Imaging Technology

JULY 25, 2023

The ubiquitous expression of FAP in cancer-associated fibroblasts across nearly all epithelial-derived cancers paired with the low abundance in normal tissues, makes it a unique target to exploit for tumor imaging for a wide variety of cancers such as breast, pancreatic, lung and stomach cancer.

Radiopharmaceuticals 98

Radiopharmaceuticals Imaging Pharmaceutical Disease 98

AuntMinnie

JULY 10, 2024

Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).

Nuclear Medicine 117

Nuclear Medicine Radiopharmaceuticals Imaging Medicare 117

Imaging Technology

JANUARY 5, 2024

The PSMA Alpha-PET DoubLET platform technology represents a potential leap forward in the field of prostate cancer diagnostics and treatment. We focused on diagnostic accuracy, patient tolerance and convenience. It can also be used for beta-particle targeted RPT using copper isotopes.

Radiopharmaceuticals 104

Radiopharmaceuticals Clinic Nuclear Medicine Radiation 104

Imaging Technology

APRIL 10, 2024

an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. 177Lu-rhPSMA-10.1,

Radiopharmaceuticals 105

Radiopharmaceuticals Radiosensitivity Medical Diagnostic 105

Open Medscience

NOVEMBER 17, 2023

Gallium, predicted by Mendeleev, now revolutionises medical diagnostics with its unique radiopharmaceutical applications in oncology. The post Gallium Radiopharmaceuticals in Medical Imaging appeared first on Open Medscience.

Radiopharmaceuticals 59

Radiopharmaceuticals Medical Imaging Medical Imaging 59

Imaging Technology

SEPTEMBER 20, 2023

a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX biology-guided radiotherapy.

Pharmaceutical 105

Pharmaceutical Radiopharmaceuticals Radiation Diagnostic 105

Open Medscience

AUGUST 11, 2024

Radiopharmaceuticals in diagnostics provide critical insights into disease processes, improving accuracy, patient care, and treatment outcomes significantly. The post The Transformative Power of Radiopharmaceuticals in Diagnostics appeared first on Open MedScience.

Radiopharmaceuticals 52

Radiopharmaceuticals Diagnostic Patient Care Disease 52

Radiology Business

NOVEMBER 20, 2024

The Australian company will secure exclusive worldwide rights to a suite of diagnostic and therapeutic candidates geared toward urological cancers.

Radiopharmaceuticals 105

Radiopharmaceuticals Imaging Diagnostic 105

Imaging Technology

JULY 11, 2023

The ubiquitous expression of FAP in cancer-associated fibroblasts across nearly all epithelial-derived cancers paired with the low abundance in normal tissues, makes it a unique target to exploit for tumor imaging for a wide variety of cancers such as breast, pancreatic, lung and stomach cancer.

Radiopharmaceuticals 75

Radiopharmaceuticals Imaging Pharmaceutical Disease 75

Imaging Technology

JUNE 15, 2023

The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use.

Radiopharmaceuticals 98

Radiopharmaceuticals Pharmaceutical Nuclear Medicine PET Scan 98

Open Medscience

NOVEMBER 12, 2023

Technetium-99m, discovered in 1937, transformed medical imaging with its versatile and safe diagnostic applications. The post Technetium-99m Radiopharmaceuticals in Advanced Medical Imaging appeared first on Open Medscience.

Radiopharmaceuticals 59

Radiopharmaceuticals Medical Imaging Medical Imaging 59

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Chief Executive Officer of Blue Earth Diagnostics. Gauden , D.Phil.,

Diagnostic 97

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 97

Open Medscience

JANUARY 1, 2024

Zirconium radiopharmaceuticals enhance nuclear medicine with precise diagnostics and potential therapeutic applications. The post Zirconium Radiopharmaceuticals in Nuclear Medicine appeared first on Open Medscience.

Nuclear Medicine 59

Nuclear Medicine Radiopharmaceuticals Diagnostic Medical 59

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 PET imaging currently under review by the U.S.

Diagnostic 98

Diagnostic Radiopharmaceuticals Imaging Radiation 98

Imaging Technology

JUNE 21, 2023

POSLUMA (formerly referred to as to as 18F-rhPSMA-7.3 ) is an optimized, high-affinity radiohybrid (rh) Prostate-Specific Membrane Antigen (PSMA)-targeted PET imaging agent. Chief Executive Officer of Blue Earth Diagnostics Ltd. Blue Earth Diagnostics is at Booth 6025 and PETNET Solutions is at Booth 6075. Gauden , D.Phil.,

Diagnostic 97

Diagnostic Radiopharmaceuticals Imaging Medicare 97

Imaging Technology

NOVEMBER 7, 2024

Under the new policy, CMS will unpackage and pay separately for diagnostic radiopharmaceuticals with per-day costs exceeding $630, removing financial barriers that have long hindered patient access to essential nuclear medicine diagnostic procedures.

Nuclear Medicine 97

Nuclear Medicine Radiopharmaceuticals Medicare Diagnostic 97

Open Medscience

DECEMBER 31, 2023

Lutetium radiopharmaceuticals significantly advance targeted cancer treatment and diagnostic capabilities. The post Lutetium Radiopharmaceuticals in Medicine: A Comprehensive Review appeared first on Open Medscience.

Radiopharmaceuticals 59

Radiopharmaceuticals Diagnostic Medical Imaging 59

Open Medscience

JANUARY 11, 2024

Theranostics merges diagnostics and therapy, revolutionising personalised medicine with genetic profiling and targeted treatment strategies. The post Theranostics Bridging Diagnostics and Therapy for Targeted Treatment appeared first on Open Medscience.

Diagnostic 115

Diagnostic Radiopharmaceuticals Medical Imaging 115

Open Medscience

NOVEMBER 11, 2023

Copper radiopharmaceuticals offer groundbreaking diagnostic and therapeutic applications, revolutionising nuclear medicine, particularly in oncology and cardiology. The post Exploring Copper Radiopharmaceuticals: Innovations and Applications in Nuclear Medicine appeared first on Open Medscience.

Nuclear Medicine 59

Nuclear Medicine Radiopharmaceuticals Diagnostic Medical 59

Imaging Technology

JULY 5, 2024

68Ga-DOTA-RM2 will be used as a companion diagnostic. While new PSMA-targeted diagnostics and therapeutics are transforming prostate cancer care, there are many patients for whom PSMA-targeted therapy may not be appropriate,” said Brian Markison, Lantheus CEO. For more information: www.lantheus.com Friday, July 5, 2024 - 06:00

Diagnostic 105

Diagnostic Radiopharmaceuticals Disease IT 105

Imaging Technology

SEPTEMBER 27, 2023

PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Chief Executive Officer of Blue Earth Diagnostics. from October 1 to 4, 2023. Gauden , D.Phil., Kuo, MD, Ph.D.,

Diagnostic 105

Diagnostic Radiation Oncology Radiation Clinic 105

Diagnostic Imaging

JUNE 28, 2023

In a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, Phillip Kuo, M.D.,

Radiopharmaceuticals 58

Radiopharmaceuticals Nuclear Medicine Imaging 58

AuntMinnie

APRIL 4, 2024

Life Molecular Imaging (LMI) and Sofie Biosciences have begun offering the Neuraceq ( florbetaben F-18) PET radiotracer produced at Sofie's radiopharmaceutical manufacturing site in Cleveland, Ohio. With this expansion, LMI continues driving commercial sales of Neuraceq around the U.S.

Radiopharmaceuticals 81

Radiopharmaceuticals Imaging Disease Diagnostic 81

Imaging Technology

JULY 28, 2023

It is the first and only FDA-approved, PSMA-targeted imaging agent developed with proprietary radiohybrid (rh) technology. POSLUMA is widely available through 36 radiopharmacies in the national network of Blue Earth Diagnostics’ commercial U.S. Chief Medical Officer of Blue Earth Diagnostics. manufacturer and distributor. “The

Diagnostic 98

Diagnostic Clinic Radiopharmaceuticals Radiation 98

Imaging Technology

JUNE 10, 2024

The award was announced by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its 2024 Annual Meeting, June 8-11 in Toronto. More recently, she and her collaborators developed a PET imaging agent for vaso-occlusive crisis in sickle cell disease, recently approved for human studies by the FDA as an Investigational New Drug.

Nuclear Medicine 104

Nuclear Medicine Radiopharmaceuticals Disease Imaging 104

Imaging Technology

APRIL 5, 2024

milla1cf Fri, 04/05/2024 - 11:31 April 5, 2024 — RLS Radiopharmacies , America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler.

Radiopharmaceuticals 52

Radiopharmaceuticals Radiation Oncology Radiation Quality and Compliance 52

AuntMinnie

JULY 12, 2024

As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. Image courtesy of Washington University. "We Nuclear Regulatory Commission and is an integral part of a theranostics practice.

Nuclear Medicine 102

Nuclear Medicine Radiation Oncology Radiopharmaceuticals Radiation 102

AuntMinnie

JUNE 3, 2024

With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., Siegel told AuntMinnie.com. "My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.

Nuclear Medicine 105

Nuclear Medicine Radiopharmaceuticals Radiation Radiation Oncology 105

Diagnostic Imaging

JANUARY 12, 2024

The FDA has accepted Lantheus' abbreviated new drug application for a generic Lutathera, just months after Novartis announced positive phase 3 data supporting a first-line indication for the radiopharmaceutical in neuroendocrine tumors.

Radiopharmaceuticals 120

Radiopharmaceuticals 120

AuntMinnie

SEPTEMBER 30, 2024

A radiopharmaceutical therapy that lengthens progression-free survival for patients with neuroendocrine cancer could help treat meningioma sufferers, according to research presented at the American Society for Radiation Oncology (ASTRO) meeting. Nearly 80% of patients in our study were progression-free after six months," he said.

Radiation Oncology 119

Radiation Oncology Radiopharmaceuticals Radiation Clinic 119

Imaging Technology

APRIL 3, 2023

produced, non-uranium based Mo-99 for use in diagnostic imaging. Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit.

Medical 98

Medical Radiopharmaceuticals Pharmaceutical Radiation 98

AuntMinnie

OCTOBER 25, 2024

He earned his medical degree at the University of Alabama School of Medicine and completed a residency in diagnostic radiology at the University of Florida. 7-tesla MRI gets us closer in imaging to our pathology colleagues, and offers many new possibilities for better treatment," he said. Perry Pickhardt, MD. He served in the U.S.

Nuclear Medicine 141

Nuclear Medicine Education Radiology Technologist Radiation Science 141

Imaging Technology

JULY 25, 2024

Medical isotopes are essential for a wide range of diagnostic and therapeutic procedures, including cancer treatments and advanced imaging techniques. This agreement could be instrumental to the radiopharmaceutical industry and patient health. a subsidiary of BWX Technologies, Inc.

Medical 105

Medical Radiopharmaceuticals Pharmaceutical Clinic 105

Imaging Technology

JUNE 29, 2023

milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 Blue Earth Diagnostics received U.S.

Clinic 98

Clinic Nuclear Medicine Radiopharmaceuticals Radiation 98

Open Medscience

AUGUST 8, 2019

Imaging agents can be used to evaluate organ function, detect cancer, measure blood flow and follow metabolic processes. The post Radiometals for diagnostic imaging and theranostics appeared first on Open Medscience.

Diagnostic Imaging 52

Diagnostic Imaging Diagnostic Imaging Radiopharmaceuticals 52

Diagnostic Imaging

JUNE 9, 2024

shared her perspective on a number of topics affecting nuclear medicine, ranging from isotope availability and reimbursement challenges for diagnostic radiopharmaceuticals to increasing patient interest in PET imaging. In a recent interview, Cathy Cutler, Ph.D.,

Nuclear Medicine 64

Nuclear Medicine Radiopharmaceuticals Diagnostic Imaging 64

Imaging Technology

OCTOBER 11, 2023

based company, to develop, manufacture and commercialize SOFIE’s Gallium-68 and Fluorine-18 labelled diagnostics targeting fibroblast activation protein (FAP). Its Molecular Imaging portfolio combines established proprietary products across cardiology, neurology and oncology. Financial terms were not disclosed.

Healthcare 105

Healthcare Healthcare Pharmaceutical Radiopharmaceuticals 105